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Atopic dermatitis (AD) patients are massively colonized with Staphylococcus aureus
(S. aureus) in lesional and non-lesional skin. A skin infection may become systemic if
left untreated. Of interest, the incidence of multi-drug resistant S. aureus (MRSA) in
AD patients is higher as compared to a healthy population, which makes treatment
even more challenging. Information on the specific genetic background of S. aureus
accompanying and/or causing AD flares would be of great importance in terms of
possible treatment option development. In this review, we summarized the data on the
prevalence of S. aureus in general in AD skin, and the prevalence of specific clones
that might be associated with flares of eczema. We put our special interest in the
presence and role of staphylococcal enterotoxins as important virulence factors in the
epidemiology of AD-derived S. aureus. Also, we summarize the present and potentially
useful future anti-staphylococcal treatment.
Keywords: epidemiology of S. aureus, MRSA, staphylococcal enterotoxins, antistaphylococcal photodynamic
treatment, virulence factor
INTRODUCTION
Atopic dermatitis (AD), also known as atopic eczema, is a chronic and relapsing inflammatory
skin disorder. It may coexist with other atopic conditions: allergic rhinitis (hay fever), bronchial
asthma and food allergy. AD mainly affects infants and young children. Nevertheless, it can persist
or appear during puberty and adulthood. AD occurs commonly in 15–30% of children and 2–10%
of adults worldwide (Silverberg, 2017).
In 1980, Hanifin and Rajka proposed criteria for diagnosing AD. According to the published
guidelines, patients diagnosed with AD should present three or more basic features (e.g., pruritus,
lichenification, atopic history) and three or more minor features (e.g., xerosis, early age of onset,
food intolerance) (Hanifin and Rajka, 1980). Furthermore, various scoring systems have been
established to measure disease severity. SCORAD (Severity Scoring Index of Atopic Dermatitis)
evaluates the intensity of atopic signs in general in addition to the symptoms (pruritus and sleep)
(Kunz et al., 1997), whereas EASI (Eczema Area and Severity Index) evaluates the severity of AD in
four different parts of the body (head and neck, upper limbs, trunk and lower limbs) (Hanifin et al.,
2001; Housman et al., 2002). SASSAD (Six Area Six Sign Atopic Dermatitis Atopic Score) less used
includes six signs of AD (cracking, dryness, erythema, excoriation, exudation, and lichenification),
their severity in a four-point scale (0—absent, 1—mild, 2—moderate and 3—severe) on the most
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FIGURE 1 | Various scoring systems for diagnosing atopic dermatitis.
following sites of different parts of the body (head and neck, arms,
hands, trunk, legs, and feet) (Figure 1; Berth-Jones and Berth-
Jones, 1996).
Currently, AD is considered a multifactorial skin disorder,
with still not fully understood pathogenesis. The development
of AD is a result of interactions between skin barrier defects
and genetic, immunological and environmental factors (e.g., dust
mite, tobacco smoke, soap, diet, air pollution, hygiene, stress)
(Ring et al., 1992; Bonamonte et al., 2019). Patients suffering from
atopic eczema revealed significantly reduced quality of life due
to itching, which leads to sleep disturbances (Blome et al., 2016).
The severe form of AD had a significant impact on the quality of
life in adult patients compared to the mild and moderate types
of AD (Chiesa Fuxench et al., 2019). Moreover, AD is a serious
socio-economic problem in health care units because of the long
treatment duration and financial costs (Carroll et al., 2005).
In addition to the long-term and burdensome treatment of AD
patients, colonization by Staphylococcus aureus is another serious
problem. Staphylococcus aureus is associated with the severity,
pathogenesis and exacerbation of AD.
INCREASED STAPHYLOCOCCUS
AUREUS COLONIZATION RATE FOR AD
PATIENTS
The phenomenon of S. aureus colonization in AD patients has
been known for a long time (Leyden and Marples, 1973; Hauser
et al., 1985). Hauser et al. demonstrated higher S. aureus density,
S. aureus fraction (SAF index) and total CFU/cm2 (CFU–colony
forming units) in the lesional skin in AD patients than in the
healthy control group (Hauser et al., 1985). In children suffering
from AD, S. aureus colonization rate is higher than in the healthy
group and affects 57–100% of children (Bunikowski et al., 2000;
Arkwright et al., 2001; Lo et al., 2010; Pascolini et al., 2011). More
than 40% of AD children are colonized both on the lesional skin
and in the anterior nares (Pascolini et al., 2011). In children with
AD, the carriage of the S. aureus strains in the anterior nares could
be a potential source of recolonization (Patel et al., 2001). Results
concerning S. aureus presence from AD children are summarized
in Table 1.
Regarding S. aureus colonization in adult patients, 54–100%
(Breuer et al., 2002; Tomi et al., 2005; Gong et al., 2006; Kim
et al., 2009; Na et al., 2012; Rojo et al., 2014; Clausen et al., 2017,
2019) suffering from AD were colonized by this species. S. aureus
isolates formed a reservoir in the nose in AD patients. It can be
diffused by autotransmission on the skin area (Breuer et al., 2002).
The most colonized site is lesional skin (56–96.2%) (Matsui et al.,
2000; Park et al., 2016; Totté et al., 2016; Alsterholm et al.,
2017), nose (46.1–64.1%) (Na et al., 2012; Park et al., 2016; Totté
et al., 2016; Clausen et al., 2017), and non-lesional skin (28–39%)
(Matsui et al., 2000; Totté et al., 2016; Clausen et al., 2017). Several
studies demonstrated that 65–77.3% (Breuer et al., 2002; Tomi
et al., 2005; Na et al., 2012) of AD patients were colonized both in
the anterior nares and on the skin, whereas only 10.2% of healthy
control subjects were colonized on the skin (Matsui et al., 2000).
Alsterholm et al. (2017) found that 55% of the AD patients were
persistent carriers of S. aureus. Moreover, persistent S. aureus
carriers had a higher SCORAD than intermittent carriers or non-
carriers. It turns out that not only the nose but also the skin could
be an important reservoir of S. aureus in AD patients (Alsterholm
et al., 2017). Frequent recolonization by S. aureus between nose
and skin was observed, which can contribute to the severity of
AD (Chiu et al., 2009). Results concerning the distribution of
S. aureus in adults are summarized in Table 2.
High S. aureus colonization rate is observed in both
groups, children and adults. Colonization rate increases with
the severity of the AD, and it acts as an aggravating
factor exacerbating inflammation (Breuer et al., 2002). Also,
colonization with S. aureus in AD patients could be a potent
risk of various invasive infections, e.g., bacteremia, septic
shock, osteomyelitis, necrotizing pneumonia, or septic arthritis
(Patel and Jahnke, 2015).
MRSA VS. MSSA DISTRIBUTION IN
ATOPIC DERMATITIS
Among S. aureus isolates, methicillin-resistant S. aureus (MRSA)
constitutes an important and significant group that requires
particular concern. MRSA is a group of strains that are resistant
to multiple β-lactam antibiotics (cephalosporins, carbapenems,
monobactams, and penicillins). This phenotype results in limited
treatment options, including for skin infections (Rangel and
Paller, 2018). It has been demonstrated that among S. aureus
strains colonizing AD patients, the percentage of MRSA is 4–13
times higher than in a healthy population (Suh et al., 2008; Lo
et al., 2010).
Currently, three profiles of MRSA are distinguished:
hospital-associated (HA-MRSA), community-associated (CA-
MRSA), and livestock-associated MRSA (LA-MRSA). Initially,
epidemiological investigations indicated that MRSA infections
related only to hospitalized patients (HA-MRSA). However,
later it turned out that MRSA can also be isolated from infected
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TABLE 1 | The distribution of S. aureus colonization and toxins production in children with atopic dermatitis.
References Examined groups Sites of isolation Colonization staphylococcus
aureus
Toxins production














AD patients 60 (81%) were S. aureus
positive [including 40 (53%) toxigenic
S. aureus strains]
Healthy controls 5 (20%) were
S. aureus positive [including 1 toxigenic
S. aureus strain]
AD patients sea: 12, seb: 9,
sec: 12, sed: 3, tsst-1: 9
Healthy controls sea: 1






Each of the examined patients was
colonized
Skin sea: 3 (11%), seb: 1 (4%),
sec: 7 (25%), sed: 1 (4%), see:
0, seg&sei: 6 (21%), seh: 0,
tsst-1: 3 (11%)
Nose sea: 2 (7%), seb: 0, sec:
3 (11%), sed: 1 (4%), see: 0,
seg&sei: 5 (17%), seh: 1 (4%),
tsst-1: 2 (7%)






Area of active eczema
Perineum
No data sea: 8 (29%), seb: 1 (4%), sec:
1 (4%), sed: 0 (0%), tsst-1: 0
(0%)




Children with AD and
SSTI (n = 20)
Healthy controls
(n = 490)
The anterior nares Children with AD 67 isolates were
positive for S. aureus
(23 MRSA and 44 MSSA)
Children with AD and SSTI 20 isolates
were positive for S. aureus
(12 MRSA and 8 MSSA)
Healthy controls 170 isolates were
positive for S. aureus
(44 MRSA and 126 MSSA)
Results from molecular
characteristics of 79 MRSA
isolates from 643 children
Children with AD sea: 1 (4%),
seb: 20 (87%), sec: 2 (9%),
sed: 0, seg/sei: 1 (4%), seh: 1
(4%), tsst-1: 2 (9%),
Children with AD and SSTI sea:
0, seb: 12 (100%), sec: 0, sed:
0, seg/sei: 0, seh: 1 (8%),
tsst-1: 0,
Healthy controls sea: 3 (7%),
seb: 28 (64%), sec: 11 (25%),
sed: 1 (2%), seg/sei: 11 (25%),
seh: 0, tsst-1: 7 (16%)









Children with AD 66 patients (57%)
- lesional skin and nares: 47 (40.2%)
- nares: 19 (16.2%)
- uninvolved skin: 4 (3.4%)
Healthy children 18 patients (20%)
- nares: 18
- uninvolved skin: 0
Enterotoxins 71 positive among
90 S. aureus strains
Tsst-1 40 positive among 90
S. aureus strains











Infants- acute lesion: 50% (18/36)
- chronic lesion: 18.5% (28/151)
Children- acute lesion: 80% (44/55)
- chronic lesion: 41.8% (90/215)
No data











All S. aureus strains were MSSA except
one MRSA isolated from the skin
Skin and nasal isolates seb: 1
(2.5%), sec: 2 (5%), tsst-1: 22
(55%)
Skin isolates seb: 0, sec: 2
(7.7%), tsst-1: 13 (50%)





Nasal swabs 97/117 of patients (82.90%) were
colonized with S. aureus
- 26/97 (22.22%) MRSA
- 71/97 (60.68%) MSSA
No data
Frontiers in Microbiology | www.frontiersin.org 3 January 2021 | Volume 11 | Article 567090
fmicb-11-567090 December 31, 2020 Time: 11:20 # 4
Ogonowska et al. Staphylococcus aureus in Atopic Dermatitis
TABLE 2 | The distribution of S. aureus colonization and toxins production in adults with atopic dermatitis.
References Examined groups Sites of isolation Colonization of staphylococcus
aureus
Toxins production
Zollner et al. (2000)
Germany
AD patients (n = 33)







healthy skin of the
elbows
AD patients: 23/33 (69.70%)
Atopic controls: 9/21 (42.86%)
Healthy controls: 15/50 (30%)
AD patients 13/23 (57%)
isolates produced SEs
seb (5/13, 38%), sec (1/13,
8%), sed (1/13, 8%), tsst-1
(3/13, 23%)
Atopic controls 3/9 (33%)
isolates produced SEs
sea (2/3, 66%), seb (1/3, 33%),
tsst-1 (1/3, 33%)
Healthy controls 5/15 (33%)
isolates produced SEs
sea (1/5, 20%), seb (1/5, 20%),
tsst-1 (3/5, 60%)















Cutaneous and nasal isolates
from 32 patients were included
in the study.




sea = sed > seb > sec = tsst-1
Nose sed > seb > sea = sec
tsst-1 was not detected











dermatitis (n = 22)
Group 1 isolates: 4 the
most affected
eczematous lesions
No data Group 1 sea: 37 (47%), seb: 33
(42%), sec: 23 (29%), sed: 38
(49%), see: 33 (42%), sei: 38
(49%), tsst-1: 27 (35%)
Group 2 sea: 8 (27%), seb: 3
(10%), sec: 9 (30%), sed: 4
(13%), see: 6 (20%), sei: 10
(33%), tsst-1: 12 (40%)
Group 3 sea: 4 (18%), seb: 2
(9%), sec: 2 (9%), sed: 1
(4.5%), see: 6 (27%), sei: 10
(45%), tsst-1: 11 (50%)











35 of the 42 patients (83.3%) sea: 35 (97.2%), seb: 1 (2.8%),
sec: 0, sed: 5 (13.9%), see: 0,
tsst-1: 35 (97.2%)










- acute lesions: 87.5% (35/40)
- chronic lesions: 48.9% (93/190)
No data
















Clausen et al. (2019)
Denmark
AD patients (n = 63) Lesional skin
Non-lesional skin
Nose
34 of patients (54%):
- lesional skin: 33%
- non-lesional skin: 10%
- nose: 41%
No data
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people that have not been exposed to healthcare-related risks
(CA-MRSA). The first outbreak of CA-MRSA was described
in 1981 in the United States (Saravolatz et al., 1982) and
nowadays is associated with skin and soft tissue infections
(King et al., 2006; Chung et al., 2008). The skin of patients
with AD could be a favorable reservoir for CA-MRSA. In
the United States, 18.3% of AD patients are colonized with
CA-MRSA (Chung et al., 2008). Colonization with MRSA
constitutes the best-known risk factor for developing infection
and MRSA can be easily transferred via direct skin-to-skin
contact in the public settings, e.g., gyms, thus spreading the
bacteria further. Reported in recent years, LA-MRSA is of animal
origin, but it has also been detected in humans (van Cleef
et al., 2011). It typically causes skin and soft tissue infections
(SSTI) as well as more severe infections, similar to HA- and
CA-MRSA. Some epidemiological data on the prevalence of
LA-MRSA skin and soft tissue infections account for 15% of
all MRSA SSTI infections in the community (Butaye et al.,
2016). However, similar data in the AD population are not
currently available.
Nasal carriage of S. aureus plays a vital role in the
epidemiology and pathogenesis of AD disease. Nevertheless, the
distribution of MRSA strains among AD patients is still divergent
in the worldwide population. Among S. aureus-positive swabs
from the anterior nares of AD patients, 34% were MRSA, in
contrast to 26% from healthy children (Lo et al., 2010). In
another study carried out in Brazilian AD children, 22.22%
of S. aureus isolated strains were MRSA. On the other hand,
when Korean AD children skin lesions were screened, 18.4%
S. aureus strains were MRSA. Finally, among the isolates from
AD children from Italy, only 7.9% were MRSA (12.8% from
the skin lesion and 4.5% from the nose) (Chung et al., 2008;
Pascolini et al., 2011). Moreover, they indicated that children
with AD who had contact with wounds and pus at home or with
persons colonized by MRSA had an increased risk of acquisition
MRSA. In the case of adults with AD, the overall distribution
of MRSA isolates seems to be much lower (Kim et al., 2009)
or even absent (Rojo et al., 2014), as compared to the children
in AD population.
Studies mentioned above indicate that the distribution
of MRSA isolates among AD patients reflects an increased
prevalence of MRSA in the AD population as compared to
healthy ones, in particular in children. Notably, among patients
expressing a severe type of AD, a higher risk of MRSA acquisition
with time was reported in comparison to patients with a mild or
moderate AD type (Abad et al., 2019).
FACTORS PREDISPOSING TO THE
S. AUREUS COLONIZATION
One of the main factors predisposing to the S. aureus colonization
are changes in the composition of lipids and fatty acids in
the skin. In the epidermis (especially in the stratum corneum)
significantly lower level of ceramides and higher amount of
cholesterol was observed (Figure 2; Murata et al., 1996; Di Nardo
et al., 1998). The reduction of skin lipids level could explain the
role of these components in maintaining the hydration of the
skin (Coderch et al., 2003). Similarly, ceramides and sphingosine
levels are reduced in the stratum corneum of AD patients, which
may favor S. aureus colonization. It was shown that sphingosine
reveals the antimicrobial effect against S. aureus (Arikawa et al.,
2002). Furthermore, S. aureus that colonized patients with AD
produced an enzyme—ceramidase (Ohnishi et al., 1999). Since
ceramides play a crucial role in the water-retaining in the stratum
corneum, ceramidases action lead to the deficiency of ceramides
molecules, which is associated with increasing trans-epidermal
water loss and characteristic dry, cracked skin in patients with
AD (Arikawa et al., 2002).
The level of antimicrobial peptides (AMPs) and host defense
peptides (HDPs), produced by keratinocytes such as dermicidin,
human β-defensins and cathelicidin–LL-37 are markedly reduced
in AD skin, which also conduces to S. aureus colonization and
infection (Ong et al., 2002; Roll et al., 2004). These peptides
efficiently inhibit S. aureus growth (Niyonsaba et al., 2017). Th2
cytokines IL-4, IL-13, and IL-31, which are overexpressed in
AD patients, inhibited the expression of the human β-defensins
genes (hBD-2 and hBD-3). It is probably one of the factors
that contribute to the proliferation of S. aureus, disturbance of
microbiota composition and implication in the AD pathogenesis
(Kanda and Watanabe, 2012).
Filaggrin (FLG) is an epidermal protein which is a part of
the stratum corneum, the main barrier of the skin. Filaggrin is
responsible for hydration, maintaining epidermal homeostasis,
creating chemical, and structural barrier function (O’Regan
and Irvine, 2008). The primary function is bonding keratin
cytoskeleton in the process of keratinocytes maturation in the
skin layer (Candi et al., 2005; Brown and McLean, 2012).
Filaggrin can act as a scaffold for the connection of the lipids
layers (O’Regan et al., 2008). As a result of filaggrin breakdown,
pyrrolidone carboxylic acid (PCA) and urocanic acid (UCA)
are formed, which are the composition of natural moisturizing
factor (NMF) (Rawlings et al., 1994; O’Regan et al., 2008).
This factor plays a crucial role in maintaining hydration of
the stratum corneum and the appropriate pH of the skin
(Rawlings et al., 1994; O’Regan et al., 2008). Nowadays, most
studies proved that filaggrin loss-of-function mutations play an
important role in the aggravation process in patients with AD
(Brown and McLean, 2012). Reduced levels of filaggrin cause
skin inflammation, resulting from the increasing penetration of
allergens or irritants (Gruber et al., 2011). Furthermore, the levels
of filaggrin and NMF are significantly decreased in AD patients
(Brown and McLean, 2012). Also, PCA and UCA, filaggrin
breakdown products have been in vitro shown to impact S. aureus
cell density and growth rate (Miajlovic et al., 2010). Notably, in
patients with a mutation in the filaggrin gene (FLG) increased
S. aureus colonization was showed as compared to wild-type
patients (Clausen et al., 2017).
In the skin, pH level plays a key role in maintaining the proper
barrier function in the epidermis, protection against pathogens
and control of the process of desquamation. The pH level of
healthy skin is slightly acidic (4.0–6.0). Fatty acids–products of
the phospholipid hydrolysis in sebum and sweat, maintain the
low pH level (Chan and Mauro, 2011). There is an association
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FIGURE 2 | Factors predisposing to the S. aureus colonization.
between the lower pH level and the reduced expression of
proteins, in particular, those involved in adherence to the skin by
S. aureus (e.g., protein A, clumping factor B, fibronectin-binding
protein A) (Leung, 2013). Therefore, changes in the pH level
toward more alkaline are one of the factors, facilitating S. aureus
colonization and growth in AD patients (O’Regan and Irvine,
2008; Proksch et al., 2008; Clausen et al., 2019). The pH 7.0–
8.0 has been shown optimal for S. aureus adhesion to human
keratinocytes (Mempel et al., 1998).
NO MAJOR S. AUREUS CLONES COULD
BE ASSIGNED TO ISOLATES FROM AD
PATIENTS
Due to the frequent occurrence of S. aureus in patients with
AD, as well as the growing number of scientific reports on
the mechanisms of immune response induction by specific
virulence factors, a natural question arises whether there are
selected S. aureus clones/types associated with the disease.
A “gold standard” to determine the clonality of S. aureus strains,
especially MRSA, is PFGE (Pulsed Field Gel Electrophoresis) (He
et al., 2014). A specific “DNA fingerprint” for an individual clone
is assigned to a specific pulsotype (e.g., A, B, C) (Golding et al.,
2015). PFGE genotyping of S. aureus indicated that among the
isolates from AD children, the most common pulsotype was B
(48%). In contrast, pulsotype A was the most frequent in the
healthy control group (64%) (Lo et al., 2010). However, Lomholt
et al. (2005) indicated that 28 various S. aureus PFGE pulsotypes
could be reported for AD patients.
With the application of MLST (multi-locus sequence typing),
that is another useful method of microbial genotyping, Kim
et al. (2009) revealed that sequence types ST188, ST1, ST5,
and ST513 were the most frequently identified in the studied
adolescent or adult patients with AD (19.4, 13.9, 11.1, and 11.1%,
respectively). These data demonstrated the absence of prevailed
genotype. Additionally, most of the detected lineages (especially
ST188 and ST1) were community-acquired strains in contrast to
only a single ST5, which in Korea is associated with hospital-
acquired strains.
Clausen et al. focused on the distribution of clonal complexes
(CCs) determined based on spa typing among strains isolated
from AD patients. As much as 92% of S. aureus isolates
demonstrated identical spa types in three studied sites (nose,
lesional, non-lesional skin). The most frequent spa types were
t008, t084, t127, and t948 (Clausen et al., 2017). Different results
were obtained by Kim et al. (2009), who identified t189 (19.4%)
as the most frequent type, followed by t127 (13.9%), t164 (11.1%),
and t304 (8.1%). These results confirm the observation on the
heterogeneity of S. aureus strains isolated from AD patients.
Applying yet another typing method, namely, CC typing,
Yeung et al. (2011) proved that in AD patients (adults and
children), the most common clonal complex was CC45 (34 of
S. aureus isolates out of 160), CC5 (23 isolates), CC15 (22
isolates), CC1 (21 isolates), CC30 (11 isolates), and CC398
(8 isolates). In another study by Rojo et al. (2014) two
groups of patients were included as follows: AD patients
(n = 32) and patients who suffered from other atopic diseases
(asthma, allergic rhinitis or food allergy, n = 31). Among
AD patients, the most frequent CC was CC5 (31.2%), CC15
(18.7%), CC30 (18.7%), and CC45 (15.6%), whereas CC30
mostly prevailed in the control group (48.3%) (Rojo et al.,
2014). Also, it was demonstrated that 95% of examined samples
from AD patients belonged to the same clonal complex in
three sampling sites (nose, lesional and non-lesional skin).
Interestingly, the authors observed that CC1 was identified more
frequently in patients with filaggrin mutations (Clausen et al.,
2017). Similarly, Harkins et al. found in the inflamed skin
of children with AD that the most prevalent clonal complex
was CC1 (20%), whereas CC30 (33%), and CC45 (22%) were
predominantly detected in the anterior nares of healthy children
(Harkins et al., 2018).
Temporal variation of CC types in S. aureus was observed
in patients with mild to moderate AD where 52% of patients
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examined during follow up study were colonized by the same
CC type. Interestingly, nearly half of the studied patients (48%)
demonstrated different CC types during the follow-up study,
which correlated with increased SCORAD (Clausen et al., 2019).
Genetic variations present in S. aureus has been shown to
influence clinical outcome in some essential diseases (Messina
et al., 2016). The connection between clonal complex and
infections was documented for CC8 associated with sepsis,
CC30 associated with endocarditis or CC398 associated with
nasal carriage and bone and joint infection (Nienaber et al.,
2011; Spaulding et al., 2012; Valour et al., 2014). The
distribution of staphylococcal clonal complexes in AD patients
that has been analyzed throughout the recent years points
for great heterogeneity, and no specific clone/clones prevailed
in this group of patients. Moreover, observations proved that
populations of S. aureus isolated from AD patients are very
clonal, and that characteristic virulence factor variants that have
been shown to contribute to AD may occur in different clonal
lineages. This further means that this is rather unlikely to
characterize specific S. aureus lineages associated with AD and
disease severity, at least based on traditional typing methods
(Kim et al., 2009; Yeung et al., 2011; Rojo et al., 2014; Clausen
et al., 2017). The only example of a correlation between S. aureus
genetic background and AD was the one found by Clausen
et al., where CC1 clone was the most commonly detected among
AD patients (22% of all colonized patients) and significantly
more prevalent in filaggrin mutation carriers (Clausen et al.,
2018). Nevertheless, considering the above observation and the
dynamic evolution of the S. aureus species based on the survival
of only those populations that can survive in given conditions
(e.g., in a defective atopic skin), the existence of AD-specific
genotype(s) cannot be excluded. S. aureus genetic variations
that might contribute to a particular clinical outcome (like
infection of atopic skin) might be present at different levels:
clonal, gene, or at the level of gene polymorphisms. Therefore,
detailed knowledge about the bacterial genetic variation is
needed to understand better the role of S. aureus in the
pathogenesis of AD.
A NEW CONCEPT OF STRAIN-SPECIFIC
COLONIZATION OF S. AUREUS IN AD
Traditional genotyping methods allow the differentiation of
staphylococcal isolates from AD patients. These methods,
however, have their resolution limitations, which did not
allow identification of specific genetic features of AD-derived
S. aureus. At the same time, there are functional differences
manifested by altered immune responses in the skin between
AD S. aureus strains vs. non-AD S. aureus strains. It was
observed that only AD-derived S. aureus strains altered T
cell response via Langerhans cells (Iwamoto et al., 2017), and
only AD-derived strains accumulated in lysosomes and induced
IL-1α production via Toll-like receptor 9 (Moriwaki et al.,
2019). The observed differences have been attributed to surface
proteins (Iwamoto et al., 2017; Moriwaki et al., 2019). In line
with those reports, S. aureus isolated from AD but not from
healthy carriers induced strong inflammation in the mouse
model of AD (Byrd et al., 2017). Whole-genome sequencing
of AD-derived S. aureus revealed genes coding for proteins
associated with infection, carotenoid production, or β-lactam
resistance to be associated with AD colonization (Byrd et al.,
2017). Analyzing AD microbiome suggests that AD patients
may be preferentially colonized by those S. aureus strains
that can synthesize tryptophan (Fyhrquist et al., 2019). It was
experimentally shown, however, that tryptophan metabolites on
atopic skin are significantly reduced, and therefore strains that do
not require exogenous tryptophan for growth may be preferred
(Yu et al., 2019). The concept of specific S. aureus isolates that
have a more significant potential to colonize atopic skin or induce
an immune effect in AD patients has developed significantly
in recent years. Mainly due to the results of studies linking
the production of S. aureus δ-toxin with allergic skin diseases
(Nakamura et al., 2013).
Staphylococcus aureus once established on the skin, promotes
inflammation through multiple pathways. Recent work from
several laboratories has advanced our understanding of how
the skin colonization of S. aureus promotes inflammatory skin
diseases. The general overview of the pathways involved in
S. aureus and its virulence factors contribution to AD is presented
in Figure 3.
It has been documented that S. aureus is able not only
to colonize the surface of the skin, but it also penetrates the
dermis, where the bacterium can come into direct contact with
immune cells and stimulate the production of proinflammatory
cytokines (Nakatsuji et al., 2016). S. aureus produces a range of
potent virulence factors that appeared to play a crucial role in
the inflammation process driven by the bacterium, e.g., PSMs
(phenol soluble modulins), proteases (aureolysin, V8 protease,
SspA serine protease, ScpA cysteine protease), superantigens
(staphylococcal enterotoxin A, B, TSST-1). PSMα has been shown
to induce expression of cytokines in keratinocyte cell lines as
well as in a mouse model of AD via lysis of keratinocytes, which
led to the release of inflammatory cytokines (Syed et al., 2015).
Another PSM representative, namely δ-toxin was identified in
abundant amounts in culture supernatants of S. aureus isolated
from the skin of AD patients and was shown to be a potent
inducer of mast cells degranulation suggesting for the first time
a link between S. aureus colonization and allergic skin diseases
(Nakamura et al., 2013). In this case, the mechanism of action
was different from other PSMs, as δ-toxin (PSMγ) did not
cause cell lysis but rather induced signaling pathway leading to
increased IgE, IL-4 levels (Figure 3). PSMs are critical for the
induction of IL-17 producing cells, namely γδTcells or ILC3 (type
3 lymphoid cells), which are mediators of skin inflammation in
response to S. aureus (Nakagawa et al., 2017). Depending on
the depth bacteria can reach in the skin–epidermis vs. dermis,
different host response can be elicited. Epicutaneous exposure
of S. aureus promotes inflammation via IL-36, produced mostly
by keratinocytes, whereas intradermal challenge promotes IL-1β
induction of inflammation (Liu et al., 2017). The penetration
depth has been shown to critically depend on an important group
of virulence factors produced by the bacterium, namely serine
proteases (Nakatsuji et al., 2016).
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FIGURE 3 | Pathways involved in S. aureus’ virulence factors contribution to AD. (Created with BioRender).
Toll-like receptors (TLRs), recognizing various bacterial
antigens (e.g., cell wall components), transduce a signal
through MyD88 (Myeloid differentiation primary response
gene-88) signaling pathway that leads to activation of NFκB
transcription factor and production of proinflammatory
cytokines (Kuo et al., 2013). Recently, MyD88-dependent
signaling was demonstrated a critical pathway activated in
response to staphylococcal virulence factors–PSMα (Liu et al.,
2017) and SEB (Faßbender et al., 2017). SEB is one of the
best-studied enterotoxins in the context of inflammation in
AD patients, next to SEA and TSST-1. However, in recent
years, experimental data on other members of this group of
virulence factors have emerged, expanding our understanding
of the mechanisms linking S. aureus and AD (Aziz et al., 2019;
Orfali et al., 2019). A transcriptomic approach to study
keratinocyte response to SEB or TSST-1 has been shown to
up- or downregulate more than 3,000 genes, confirming a
previously proposed signaling pathway through CD40 receptor
(Schlievert et al., 2020).
These phenomena require even more detailed knowledge,
but it turns out that S. aureus may play a vital role in
the development of AD in a strain-specific manner. The
experimental data trying to provide an answer to a question
whether S. aureus causes AD or its increased survival on
AD skin is a consequence of the disease is only starting to
emerge. More and more puzzles add up to a complete picture
that may soon allow us to understand better the molecular
mechanism of a complex relation between S. aureus and AD
(Geoghegan et al., 2018).
AN AMBIGUITY OF STAPHYLOCOCCAL
ENTEROTOXINS (SEs) IN ATOPIC
DERMATITIS
From the vast repertoire of S. aureus’ virulence factors, we will
focus on a specific group–enterotoxins, which S. aureus produces
dozens of varieties.
The pyrogenic toxin superantigen (PTSA) family is the group
of staphylococcal toxins that includes the following clusters:
staphylococcal enterotoxins (SEs), staphylococcal enterotoxin-
like toxins (SEls), and toxic shock syndrome toxin (TSST-1).
The nomenclature distinguished SEs (SEA, SEB, SEC, SED, SEE)
from SEls (SElG, SElH, SElJ, SElK, SElL, SElM, SElN, SElO, SElP,
and SElQ) is based on their causing (SEs) or not causing (SEls)
emesis in humans (Figure 4; Lina et al., 2004). Staphylococcal
enterotoxins (SEs) are known as bacterial virulence factors
that contribute to the development of many human diseases,
including toxic shock syndrome or food poisoning (Harris et al.,
1993; Balaban and Rasooly, 2000; Ortega et al., 2010; Pinchuk
et al., 2010). Many authors have indicated a role for SEs in the
course of AD by acting as factors aggravating and exacerbating
the inflammation of AD skin (Bunikowski et al., 2000; Taskapan
and Kumar, 2000; Yarwood et al., 2000; Zollner et al., 2000).
Moreover, there are indications for the causative role of SEs in
the course of AD.
The most common feature of SEs is that they possess
superantigenic properties (Spaulding et al., 2013). Superantigens
(SAgs) can bind as intact proteins to the T-cell antigen
receptor (TCR) and the major histocompatibility complex II
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FIGURE 4 | Three clusters of staphylococcal toxins.
(MHC II) outside their binding site (Fink et al., 1986) thus,
stimulating massive proliferation of nonspecific T cells and
release of proinflammatory cytokines (Harris et al., 1993;
Holtfreter et al., 2006).
Because of interest in SEs as an aggravating factor in AD,
their distribution in AD-derived S. aureus isolates was a matter
of deep interest. The main question researchers asked concerned
a potential pattern (universal vs. specific) of SEs presence in AD-
derived S. aureus. It has been known that 54–71.25% of S. aureus
isolates indicated the presence of SE genes among AD patients
(Mempel et al., 2003; Nada et al., 2012). Furthermore, a meta-
analysis of 95 studies indicated that the rate of toxins producing
S. aureus on the lesional skin fluctuated between 31.5 and 80%
(Totté et al., 2016), and was higher than in healthy controls.
The distribution of SE genes, however, varied from one studied
population to another: in Korean population sea and tsst-1 were
the most common toxin genes (Kim et al., 2009; Na et al., 2012);
in Germany, whereas one study showed that seb (38%) and tsst-
1 (23%) toxin genes were the most prevalent, and sea was not
detected (Zollner et al., 2000), other revealed that sea and sed
were most commonly detected (Breuer et al., 2002). All SEs
production patterns from adult AD patients are summarized in
Table 2. In the studies of Taiwanese children with AD, the most
frequent toxin gene was seb (87%), followed by sec (9%), tsst-1
(9%), sea (4%), seg/sei (4%), and seh (4%). The sed toxin gene was
not identified in atopic children, whereas it was predominant in
healthy children. It is worth to mention, however, that only the
MRSA population was studied (Lo et al., 2010). In England, the
most prevalent toxins were sec (25% from the skin; 11% from
the nose), seg (21% from the skin; 17% from the nose), and sei
(21% from the skin; 17% from the nose). Most cases represented
the same strains in the nose and skin (Arkwright et al., 2001). In
Spain, hla and hlg/hlgV (26, 100%), hlb (17, 65.5%), lukDE (25,
96.1%), tsst-1 (13, 50%), aur (11, 42.3%), cna (10, 38.5%), eta (4,
15.4%), and sec (2, 7.7%) were the virulence genes detected in
cutaneous isolates of children with AD (Gilaberte et al., 2015).
The observed variations in SEs distribution patterns in different
research and different AD populations indicate geographical
dependence. All SEs production patterns from AD children are
summarized in Table 1.
Interestingly, in some studies based on populations of both
children and adults, the most frequently detected genes were
not classical toxins found in 38% of AD-derived strains, but
enterotoxin gene cluster (egc), which consisted of seg, sei, sek, sem,
sen, and seo (Mempel et al., 2003). Studies on the AD cohort from
Singapore indicated that the most prevalent SEs were seb (42%),
egc (32%), and seh (29%). Interestingly, Chiu et al. proposed that
patients with a moderate type of AD were more likely to be
colonized by S. aureus possessing staphylococcal enterotoxin B
(seb) than patients with a severe type of AD (Chiu et al., 2009).
Nevertheless, another distribution pattern of toxins was observed
in Portuguese AD patients, where 76% of the examined S. aureus
strains were SE-positive, mainly for SEls: sel-m and sel-n (71.4%),
followed by sel-o and seg (66.7%) and sea and sel-l were less
frequent (29% and 33%, respectively) (Soares et al., 2013). In
the Egyptian cohort, the most prevalent gene from the S. aureus
strains isolated from the lesional skin of AD patients was seb,
followed by sec and tsst-1, sea and sed (Nada et al., 2012). All SEs
gene presence patterns from the mixed groups of AD patients are
summarized in Table 3.
It is not uncommon that AD-derived strains of S. aureus can
produce more than a single enterotoxin (Schlievert et al., 2008;
Na et al., 2012), and at significantly higher amounts (Schlievert
et al., 2008). The overall picture is even more complex when
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TABLE 3 | The distribution of S. aureus colonization and toxins production in combined groups of AD patients (both children and adults).
References Examined groups Sites of isolation Colonization of staphylococcus
aureus
Toxins production




Four groups of control
patients:
- healthy, non-atopic
patients (n = 15)
- patients with psoriasis
(n = 16)
- patients with respiratory
allergy: allergic rhinitis
and asthma (n = 10)
- patients with HIE
syndrome (n = 7)
AD lesional skin No data AD patients sea: 7 (29%), seb:
8 (33%), sec: 0 (0%), sed: 1
(4%), tsst-1: 7 (29%)








37 of 39 patients (95%) were colonized
with S. aureus on the skin
21 of 37 S. aureus isolates
(56.76%) were produced
exotoxins
sea: 2 (5.1%), seb: 13 (33.3%),
sec: 1 (2.6%), sed: 1 (2.6%),
tsst-1: 1 (2.6%), sea+seb: 1
(2.6%), seb+sec: 1 (2.6%),
seb+tsst-1: 1 (2.6%)
Matsui et al. (2000)
Japan
Patients with AD (aged
7–45, n = 26)




96.2% of AD patients on the lesional
skin
30.8% of AD patients on the
non-lesional skin
10.2% of healthy control subjects on
the non-lesional skin
Lesional skin in AD patients
(40%, 10/25 patients)
sea (4/10, 40%), seb (1/10,
10%), sec (5/10, 50%), sed
(0/10, 0%), see (0/10, 0%),
tsst-1 (3/10, 30%)
Non-lesional skin in AD patients
(37.5%, 3/8 patients)
sea (0/8, 0%), seb (1/8,
12.5%), sec (1/8, 12.5%), sed
(0/8, 0%), see (0/8, 0%), tsst-1
(3/8, 37.5%)
Healthy control group (40%,
2/5 patients)
sea (2/5, 40%), seb (0/5, 0%),
sec (0/5, 0%), sed (0/5, 0%),
see (0/5, 0%), tsst-1 (1/5, 20%)
Mempel et al. (2003)
Germany





80 of 91 patients (87.9%) were
colonized with S. aureus
120 S. aureus strains were
tested
sea: 14 (12%), seb: 7 (6%),
sec: 25 (21%), sed: 9 (8%),
see: 0 (0%), egc: 58 (48%),
seh: 0 (0%), tsst-1: 8 (7%)
Yagi et al. (2004)
Japan
Patients with AD
(n = 100) included:
- infants (n = 55)
- children (n = 28)
- adults (n = 17)
No data No data 81 isolates (81%) produce
at least one toxin
- nasal cavity: 57(70.4%)
- non-lesional area: 33(40.7%)
- dry-lesional area: 50(61.7%)
- exudative-lesional area:
61(75.3%)
sea: 22 (27.2%), seb: 44
(54.3%),
sec: 22 (27.2%), sed: 4 (4.9%),
tsst-1: 13 (16.0%)
(Continued)
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TABLE 3 | Continued
Tomi et al. (2005)
Austria
Patients with AD (3
months-60 years,
n = 25)
Healthy control (n = 25)
Lesional skin or volar
site of the elbow
Nares area
Atopic dermatitis patients 22/25
patients (88%)
- skin only: 0 (0%)
- nares only: 7 (32%)
- skin and nares: 15 (68%)
Healthy control 3/25 patients (12%)
- skin only: 1 (33%)
- nares only: 2 (67%)
- skin and nares: 0 (0%)
Atopic dermatitis patients
sec > seb > sea+sed
Healthy control None of the
strains were toxigenic
Chiu et al. (2009)
Singapore
Children and adults




91% were colonized with S. aureus
(31/34 of isolates)
85% were colonized both in the skin
and in the nose (29/34 S. aureus
strains)
sea: 6 (17.6%), seb: 13
(38.2%), sec: 4 (11.8%), sed: 3
(8.8%), egc: 10 (29.4%), seh: 9
(26.5%), sek: 5 (14.7%), sel: 2
(5.9%), tsst-1: 1 (2.9%)










- antecubital area: 10(25.6%)
- popliteal fossa: 14(35.8%)
- nasal mucosa: 18(46.1%)
- overall colonization: 25(64.1%)
Healthy control:
- antecubital area: 1(2.5%)
- popliteal fossa: 2(5%)
- nasal mucosa: 7(17.5%)




Nada et al. (2012)
Egypt
AD patients (5–26
years, n = 30)
Healthy control group
(n = 30)
From different lesions AD patients 26 (87%) patients were
colonized by S. aureus
14 isolates (54%) of 26
S. aureus strains produced
exotoxins with superantigenic
properties
sea: 1, seb: 8, sec: 4,
sed: 1, tsst-1: 4
Soares et al. (2013)
Portugal
AD patients (3–35










No data AD patients (21 S. aureus
strains were tested) –
16 (76%) were toxigenic
sea: 6 (29%)
seg: 14 (66.7%)
Other classical toxins (seb-see)
were not detected.
Rojo et al. (2014)
Spain
Patients with AD and
colonized by S. aureus




(asthma, food alergy or
rhinitis) and with
S. aureus isolated from





All of the patients included in the study
were colonized by S. aureus
AD patients sea: 14 (43.7%),
seb: 0,
sec: 7 (21.8%), see: 0,
tsst-1: 4 (12.5%)
Atopic controls sea: 14
(45.1%), seb: 3 (9.6%),
sec: 2 (6.4%), see: 0,
tsst-1: 15 (48.4%)
Merriman et al. (2016)
United States
AD patients (6–37
years, n = 103)
Lesional AD skin No data sea: 7 (6.8%), seb: 6 (5.8%),
sec: 11 (11%), sed: 16 (16%),
tsst-1: 10 (9.7%)
SE-specific IgE antibodies are considered. These were detected
in AD patients even if the genes coding for particular SEs were
absent in S. aureus. Furthermore, specific anti-SE IgE was not
detected, albeit toxigenic S. aureus was isolated from an AD
patient (Rojo et al., 2014). Such observation indicated temporal
changes in the colonization of AD patients with S. aureus
(Merriman et al., 2016).
Similarly to the association between the presence of S. aureus
and AD severity, some authors have also observed that SE-
producing S. aureus is more associated to AD severity than
SE non-producing S. aureus (Bunikowski et al., 2000; Zollner
et al., 2000; Breuer et al., 2002; Tomi et al., 2005). On the
contrary, others found no relationship between superantigens
production and the SCORAD index (Mempel et al., 2003; Rojo
et al., 2014). These differences may result from various genes
repertoire studied by different authors, e.g., Mempel et al. (2003)
and Rojo et al. (2014) included enterotoxins rarely studied by
others (see, seh, sej, and egc). Rojo et al. (2014) proved that
65.6% of S. aureus strains isolated from AD patients carried
genes encoding staphylococcal enterotoxin-like proteins, which
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function is still poorly understood. Several factors, including
estimation of the skin inflammation, the number of patients in
the studied groups, or methodological variations in SEs detection
(molecular vs. immunological), could be responsible for these
divergent observations. In fact one study found that low serum
vitamin D levels have been associated with the presence of
virulence factors tsst-1, eta, can, aur, and sec (Gilaberte et al.,
2015). Based on the available literature data and the different
methodologies used in the studies, it can be concluded that there
is a divergent distribution rather than the specific pattern of
enterotoxins producing strains among patients with AD.
METHODOLOGY PROBLEMS
CONTRIBUTING TO THE OBSERVED
DIVERGENT DISTRIBUTION OF SEs
The presented review attempts to explain possible gaps that
may lead to ambiguous results and observations as to whether
S. aureus isolated from AD patients has any specific features.
Among these ambiguities (i) differences in sampling, (ii)
isolations site, (iii) characteristics of the population studied,
(iv) selection of the control population, and finally (v) the
diagnostic method used to detect S. aureus and its virulence
factors, can be mentioned.
Most researchers used swabs from the different site of AD
patients (anterior nares, lesional, and non-lesional skin), while
others used contact plate method (Bunikowski et al., 2000; Matsui
et al., 2000; Kim et al., 2009). The contact plate method is mainly
intended for environmental monitoring of surfaces and is not
routinely used in dermatology. The advantage of using a contact
plate is a large sampling area compared to the swab method. This
allows for reliable quantitative results to be obtained. The second
difference is that the contact plate method is swift—sampling and
inoculation are performed in one step. However, this method
does not allow to sample the anterior nares. On the contrary, the
swab method is most commonly used but requires inoculation
on agar plates, and sampling covers only a small area of skin. As
a result, significant changes in bacterial flora can be overlooked.
There is currently no literature evidence comparing the results
obtained from these two techniques—swab method and contact
plate method in AD patients.
Another problem is the site of bacterial isolation. Most often,
samples are taken from AD patients skin, either lesional or non-
lesional, or both. On the other hand, anterior nares are not
included in many studies, while the nose has been proven to
be an important reservoir for S. aureus in patients with AD.
Also, S. aureus can be easily diffused on the skin area due to
autotransmission (Breuer et al., 2002). Some studies deserve
special attention because they are based on samples of S. aureus
derived from the skin (lesional and non-lesional) and anterior
nares, which allows a better understanding of the distribution of
S. aureus and its toxins from various sites of isolation (Breuer
et al., 2002; Pascolini et al., 2011; Clausen et al., 2019).
The third important issue is the selection of the studied
population. For example, some authors based their research on
the mix groups of AD patients, that included both children
and adults (Matsui et al., 2000; Zollner et al., 2000; Chiu et al.,
2009; Nada et al., 2012). It is worth mentioning that presenting
results from the mixed group of AD patients may produce
different results as if only specific age groups were considered.
This is because the course of AD is divided into three phases:
infantile, childhood, and adulthood. These phases differ in the
location of skin lesions, which may affect the results regarding
the distribution of S. aureus (Nutten, 2015). Also, aging-related
changes in bacterial flora and the distribution of S. aureus toxin
genes were observed. As an example, regarding the distribution
of the seb toxin gene, in infants, the seb gene was detected in
46.5% of S. aureus strains, in children in 58.3%, and adults in
71.4% strains (Yagi et al., 2004). It should be emphasized here that
the number of the studied groups varies considerably from study
to study, and often the groups are small, the majority include
less than 50 AD patients. This approach may not allow general
conclusions to be drawn about the variability of S. aureus toxin
genes distribution across the entire population.
The problem with the control group is also important and
might affect the overall picture of the studied phenomenon.
Some studies have omitted the control group (Arkwright et al.,
2001; Breuer et al., 2002; Mempel et al., 2003; Kim et al., 2009;
Merriman et al., 2016), while the vast majority included healthy,
non-atopic, not having accompanying allergic diseases patients,
which is the most reasonable approach (Bunikowski et al., 2000;
Matsui et al., 2000; Yagi et al., 2004; Pascolini et al., 2011;
Nada et al., 2012). However, patients with urticaria, healthy
S. aureus vagina isolates, or atopic patients with active allergic
diseases were also examined as control populations (Schlievert
et al., 2008; Park et al., 2013; Rojo et al., 2014). It may be
more difficult to observe significant differences or characteristic
trends based on the distribution of S. aureus toxins in patients
with atopic dermatitis and a group of patients with other
allergic diseases.
The last problem is the use of various diagnostic methods to
detect the studied strain of S. aureus and its virulence factors,
e.g., staphylococcal enterotoxin genes. The most popular and the
most commonly used method for the identification the S. aureus
toxin genes is PCR (polymerase chain reaction). However, many
publications do not contain information on positive and negative
controls used in PCR reactions (Yagi et al., 2004; Na et al.,
2012). It was uncertain whether the PCR reaction was carried out
following approved diagnostic standards. Only a few published
papers clearly described the positive controls used in the study
(Arkwright et al., 2001; Nada et al., 2012; Merriman et al.,
2016). In addition to the molecular method, immunoassay was
also used. To detect S. aureus enterotoxins, the technique of
reversed passive latex agglutination technique (RPLA) was used,
which gives semi-quantitative results (Bunikowski et al., 2000;
Breuer et al., 2002; Lomholt et al., 2005). As recommended by
the Thermo ScientificTM, this technique is useful for detecting
enterotoxins in a wide variety of foods.
In order to obtain comparable results, the steps should be
standardized, from sample preparation to selection of studied
groups to a uniform methodology. A universal methodology
should be created that can be used to compare results among
different laboratories and countries.
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FIGURE 5 | Different types of atopic dermatitis treatment.
TREATMENT OF ATOPIC DERMATITIS
The treatment of AD given its multifactorial pathogenesis
and chronic characteristics is challenging. It consists of
anti-inflammatory and symptomatic therapy, followed by
strengthening the damaged natural layers of skin (Figure 5).
Local treatment is based on the application of corticosteroids
or calcineurin inhibitors, as well as emollients. Topical
glucocorticosteroids are the first-line anti-inflammatory
treatment in AD (Darsow et al., 2005). These drugs are not
free from side effects, e.g., atrophy, purpura, dyspigmentation
(Weidinger et al., 2017). As a result of repeated administration
of glucocorticosteroids, the response to these compounds is
reduced (Brazzini and Pimpinelli, 2002). Anti-inflammatory
therapy, free of steroids enables topical calcineurin inhibitors
(TCIs), e.g., pimecrolimus (ASM 981/Elidel) and tacrolimus
(FK-506/Protopic) (Hanifin et al., 2004; Akdis et al., 2006). Since
2002, an ointment containing tacrolimus has been available in
the European Union countries (Rustin, 2007). The central role of
TCIs is inhibition of T lymphocytes activation and thus release
the inflammatory cytokines (Hanifin et al., 2004). In order to
restore the proper barrier function of the damaged skin, it is
essential to maintain the disturbed hydration of the epidermis.
To this end, moisturizers containing emollients and humectants
have been shown to reduce itching, flares and even reduce the
necessity of anti-inflammatory drugs (Zuuren et al., 2017). More
recently, a targeted topical therapy based on the use of crisaborole
2% ointment has been approved by the FDA to treat children and
adults with mild to moderate AD. Crisabolol action is based on
inhibiting intracellular enzyme phosphodiesterase 4 to regulate
inflammation (Eichenfield et al., 2017; Woo and Kuzel, 2019).
As for the topical types of treatment, phototherapy has been
considered an option, based on narrow-band UVB or UVA
ultraviolet light (Garritsen et al., 2014). This type of treatment is
not free from adverse effects, including photodamage or in long-
term effects skin carcinogenesis mainly due to the application of
UV light (Rodenbeck et al., 2016).
In exceptional cases, cyclosporine A (CsA), methotrexate,
azathioprine are used systemically. CsA is a calcineurin inhibitor
approved for severe AD cases. Unfortunately, its use is limited
(approved only in some EU countries, for patients > 16
y.o.), due to a wide range of side effects, e.g., hypertension,
gastrointestinal discomfort, liver dysfunction, and impairment
of renal function (with increasing creatinine and urea level in
serum) (Hanifin et al., 2004; Akdis et al., 2006; Nowicki et al.,
2015). More recently, therapy has been developed that targets
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the dominant mechanism involved in AD, namely activation of
Th2 immune pathways. Dupilumab, a fully human monoclonal
antibody targets interleukin 4 receptor alpha (IL-4Rα) that
inhibits IL-4 and IL-13 signaling (Simpson et al., 2016; Worm
et al., 2020). Another group of modern drugs that seem to be very
promising in AD treatment are inhibitors of JAK/STAT signaling
pathway, that is responsible for controlling cytokine production
and regulation (Schwartz et al., 2017). Some representative of
this group of drugs, baricitinib, abrocitinib, and upadacitinib
are currently in clinical trials (phase 3 completed) with a
positive outcome in studied populations (Ferreira et al., 2020;
Simpson et al., 2020a,b).
ANTISTAPHYLOCOCCAL TREATMENT
IN ATOPIC DERMATITIS PATIENTS
Although antimicrobial treatment is not a key treatment strategy,
it is implemented in the course of AD due to a tight correlation
of S. aureus with exacerbation events. Moreover, the state
of dysbiosis, in which lack of beneficial variability in skin
microbiome during flares of the disease, is characteristic for
AD with huge dominance of S. aureus, further justifies the
use of antistaphylococcal approaches. Treatment of S. aureus
colonization/infection in AD is mainly based on antibiotic
therapy (topical or systemic). However, overuse of antibiotics
can contribute to the development of antibiotic-resistant bacterial
strains and the loss of effective antibiotic therapy (Hung et al.,
2007). Sule et al. (2007) confirmed this hypothesis showing that
use of topical fusidic acid by AD patients in the preceding
6 months contributes to the carriage of fusidic acid-resistant
S. aureus strains. In Ireland, with wide use of fusidic acid for
skin infections and infected AD, resistance to this antibiotic
was observed in 24% more AD S. aureus strains than in
non-atopic control (Harkins et al., 2018). The combination of
the topical mupirocin ointment and topical steroids in AD
patients revealed sound therapeutic effects manifested by the
decrease in EASI and S. aureus (from 79.8% before treatment
to 40.2% after treatment). In moderate and severe AD, the
combination of antibiotic and corticosteroid could be beneficial
for patients at early stages of the disease. However, similar
clinical effects can be obtained using topical corticosteroid alone
(Gong et al., 2006).
An alternative approach in the antistaphylococcal treatment
is bleach baths with sodium hypochlorite, which do not always
bring the expected effect in reducing S. aureus colonization
in infants, children and adolescents with AD (Hon et al.,
2016; Majewski et al., 2019). The complexity of the disease
results in a single treatment option being often insufficient to
obtain a good.
FUTURE PERSPECTIVES FOR THE
ANTISTAPHYLOCOCCAL TREATMENT
Decreased variety of commensal skin microbiota and increased
S. aureus load are a key pathogenic factor in AD flares. Thus
eradication of S. aureus and restoring the natural bacterial
diversity in the skin is a crucial element in AD management,
which has only recently been recognized (Hendricks et al.,
2019). Topical antibiotic treatment decreases the number of
S. aureus but clinically, not all patients benefit from such
therapy. Besides spreading resistance to commonly applied
antibiotics is a major concern nowadays. There can be two
routes to restore the diversity of microbiome on the AD skin:
(i) reintroducing natural microbial flora on the skin and/or
(ii) decreasing the load of S. aureus. The examples of the
first approach have already been proposed (Nakatsuji et al.,
2017) and verified in some preliminary human trials based on
the application of some representatives of coagulase-negative
staphylococci (Nakatsuji et al., 2018) or yet another species,
namely Roseomonas mucosa (Myles et al., 2018). The mechanism
behind transplanting beneficial microorganisms directly onto the
skin might be based on the production of antistaphylococcal
compounds by commensal microorganisms or induction of
tolerance to a pathogen. The second approach, namely decreasing
the number of S. aureus, apart from the application of antibiotics,
bleach baths or UV-based phototherapy could be obtained by the
use of yet another light-based treatment, namely antimicrobial
photodynamic therapy (aPDT).
The aPDT method is based on the use of a nontoxic chemical
agent that is excited by visible light in the presence of oxygen.
As a result of excitation reactive oxygen species (e.g., O2−,
·OH and singlet oxygen (1O2) are produced, which damage
bacterial cell wall and cellular components (DNA, proteins,
lipids), finally resulting in microbial cell death (Cieplik et al.,
2018). One of the main advantages of this method is the local
action, with no damage to the host tissues (Wainwright et al.,
2017). It was documented that aPDT degrades protein toxins
by their chemical oxidation (Tubby et al., 2009). In contrast to
the UV-based phototherapy, aPDT is characterized by a lack of
mutagenicity (Grinholc et al., 2015). Several PS, including rose
bengal and methylene blue, applied alone or in combination
with antibiotics, have shown significant in vitro efficacy in
eradicating S. aureus growing in planktonic form as well as in
biofilm (Pérez-Laguna et al., 2017, 2018). Due to the severe
problem with S. aureus colonization in AD patients, aPDT
could be a useful tool in the antistaphylococcal treatment of
chronic or/and recurrent infections (Nakonieczna et al., 2019).
It is worth mentioning that the effectiveness of the aPDT
method does not depend on antibiotic susceptibility patterns and
resistance mechanisms.
PDT is approved in Europe for the treatment of actinic
keratosis, squamous cell carcinoma in situ, and some forms of
basal cell carcinoma. However, as an “off-label” treatment, PDT
has also demonstrated efficacy in inflammatory and infectious
dermatoses (Queirós et al., 2020). There is also one case report
describing aPDI application for skin treatment in an AD patient.
PDT using 20% 5-aminolevulinic acid (ALA) cream was applied
as a photosensitizer precursor (2 h incubation). The narrow-
band red light was used as a source of light (630 nm, 75 J/cm2,
10 min.) to treat a patient suffered from a severe lesion of AD
located on the wrists, without signs of S. aureus colonization.
After three sessions, one every other week, a reduction of
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the lichenification was observed, and the skin began to heal
(Pozzi and Asero, 2010). More recently, daylight PDT with 5-
aminolevulinic acid gel (Ameluz) was used to treat chronic hand
eczema, half of them for atopic dermatitis (Kremer et al., 2020).
After three treatments at 2 week intervals, all the patients showed
a significant clinical improvement and also in the quality of life,
without significant side effects.
The results mentioned above indicated that PDT could
be a promising alternative therapy for the treatment of skin
inflammation as well as skin colonization in AD patients, where
S. aureus is a predominant species.
CONCLUSION
The main question of this review was whether certain strains
of S. aureus are more prone to colonize, infect and deteriorate
atopic skin. Partially, the answer to this question is yes. MRSA
is more often isolated from atopic skin than healthy. However,
no specific clone can be assigned to isolates from AD patients,
as assessed by classical genotyping methods such as PFGE or
MLST. Adaptation of S. aureus to live on atopic skin can
rather be detected at a strain-specific level and identified by the
whole genome sequencing. Characterization of S. aureus from
AD patients at a strain-specific level is only just beginning to
be more available. The exact mechanisms responsible for the
interaction of S. aureus with the cutaneous immune system
has not yet been clarified. However, the latest research results
open further fields for exploration and emergence of new
strategies of treatment.
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